Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Tiv HL"'
Autor:
Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu., Zhao Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Knott AR; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wilkens MK; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Science, Molecular Biotechnology Center, University of Torino, Torino, Italy., Musteanu M; Experimental Oncology, Molecular Oncology Program, CNIO, Madrid, Spain.; Biochemistry and Molecular Biology Department, Faculty of Pharmacy, Complutense University of Madrid, Spain., Ogino A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Choi J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bahcall M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Bertram AA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Chambers ES; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Paweletz CP; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Manro JR; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana., Jänne PA; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu jens_kohler@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Publikováno v:
Molecular cancer therapeutics [Mol Cancer Ther] 2021 Apr; Vol. 20 (4), pp. 641-654. Date of Electronic Publication: 2021 Feb 03.
Autor:
Howard TP; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Oberlick EM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Rees MG; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Arnoff TE; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pham MT; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Brenan L; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., DoCarmo M; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Hong AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Pediatrics, Emory University, Atlanta, Georgia., Kugener G; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Chou HC; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Drosos Y; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Mathias KM; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Ramos P; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Seashore-Ludlow B; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Giacomelli AO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Wang X; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Molecular and Systems Biology, Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire., Freeman BB 3rd; Preclinical Pharmacokinetics Shared Resource, St. Jude Children's Research Hospital, Memphis, Tennessee., Blankenship K; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Hoffmann L; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Johannessen CM; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Stewart EA; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee. charles.roberts@stjude.org elizabeth.stewart@stjude.org william_hahn@dfci.harvard.edu.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee., Schreiber SL; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, Massachusetts., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. charles.roberts@stjude.org elizabeth.stewart@stjude.org william_hahn@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Roberts CWM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts. charles.roberts@stjude.org elizabeth.stewart@stjude.org william_hahn@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.; Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2020 Sep 15; Vol. 26 (18), pp. 4995-5006. Date of Electronic Publication: 2020 Jul 06.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Tiv HL; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Gokhale PC; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Buhrlage S; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2020 Sep; Vol. 34 (9), pp. 2543.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tiv HL; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gokhale PC; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Yang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Mar; Vol. 24 (5), pp. 2968-2980. Date of Electronic Publication: 2020 Jan 22.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Tiv HL; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Gokhale PC; Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Buhrlage S; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Liu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Bhagwat SV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA., Tiu RV; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu.
Publikováno v:
Leukemia [Leukemia] 2020 Feb; Vol. 34 (2), pp. 625-629. Date of Electronic Publication: 2019 Aug 27.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Toure AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Buhrlage S; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Winer E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Journal of cellular and molecular medicine [J Cell Mol Med] 2020 Feb; Vol. 24 (3), pp. 2145-2156. Date of Electronic Publication: 2020 Jan 14.
Autor:
Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Case AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Buhrlage SJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Liu X; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Yang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Gray N; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Adamia S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Dubreuil P; CRCM, [Signalling, Haematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée Ligue Contre le Cancer], Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille University, Marseille, France., Letard S; CRCM, [Signalling, Haematopoiesis and Mechanism of Oncogenesis, Equipe Labellisée Ligue Contre le Cancer], Inserm, U1068; Institut Paoli-Calmettes; Aix-Marseille University, Marseille, France., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.
Publikováno v:
British journal of haematology [Br J Haematol] 2019 Nov; Vol. 187 (4), pp. 488-501. Date of Electronic Publication: 2019 Jul 15.
Autor:
Bandopadhayay P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Piccioni F; Broad Institute of MIT and Harvard, Cambridge, USA., O'Rourke R; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Ho P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Gonzalez EM; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Buchan G; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Qian K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Gionet G; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Girard E; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA., Coxon M; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA., Rees MG; Broad Institute of MIT and Harvard, Cambridge, USA., Brenan L; Broad Institute of MIT and Harvard, Cambridge, USA., Dubois F; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA., Shapira O; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA., Greenwald NF; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA.; Department of Neurosurgery, Brigham and Women's Hospital, Boston, USA., Pages M; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Balboni Iniguez A; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA., Paolella BR; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA., Meng A; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Sinai C; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Roti G; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Medicine and Surgery, Hematology and BMT, University of Parma, Parma, Italy., Dharia NV; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Creech A; Broad Institute of MIT and Harvard, Cambridge, USA., Tanenbaum B; Broad Institute of MIT and Harvard, Cambridge, USA., Khadka P; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Tracy A; Broad Institute of MIT and Harvard, Cambridge, USA., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Boston, USA., Hong AL; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Coy S; Department of Pathology, Brigham and Women's Hospital, Boston, USA., Rashid R; Department of Pathology, Brigham and Women's Hospital, Boston, USA.; Department of Biomedical Informatics, Harvard Medical School, Boston, USA., Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, USA.; Ludwig Center for Cancer Research at Harvard, Harvard Medical School, Boston, USA., Cowley GS; Broad Institute of MIT and Harvard, Cambridge, USA.; Discovery Science, Janssen Research and Development (Johnson & Johnson), Spring House, PA, USA., Lam FC; Koch Institute for Integrative Cancer Research, MIT, Cambridge, USA., Goodale A; Broad Institute of MIT and Harvard, Cambridge, USA., Lee Y; Broad Institute of MIT and Harvard, Cambridge, USA., Schoolcraft K; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA., Vazquez F; Broad Institute of MIT and Harvard, Cambridge, USA., Hahn WC; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.; Department of Medicine, Harvard Medical School, Boston, USA., Tsherniak A; Broad Institute of MIT and Harvard, Cambridge, USA., Bradner JE; Broad Institute of MIT and Harvard, Cambridge, USA.; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.; Department of Medicine, Harvard Medical School, Boston, USA.; Novartis Institutes for Biomedical Research, Basel, Switzerland., Yaffe MB; Broad Institute of MIT and Harvard, Cambridge, USA.; Koch Institute for Integrative Cancer Research, MIT, Cambridge, USA., Milde T; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; CCU Pediatric Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Pediatric Oncology, Hematology, and Immunology, Center for Child and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany., Pfister SM; Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.; Division of Pediatric Neuro-Oncology, German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany., Qi J; Division of Cancer Biology, Dana-Farber Cancer Institute, Boston, USA., Schenone M; Broad Institute of MIT and Harvard, Cambridge, USA., Carr SA; Broad Institute of MIT and Harvard, Cambridge, USA., Ligon KL; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, USA.; Department of Medicine, Harvard Medical School, Boston, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, USA.; Department of Pathology, Boston Children's Hospital, Boston, USA., Kieran MW; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Santagata S; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, USA., Olson JM; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Boston, USA., Jaffe JD; Broad Institute of MIT and Harvard, Cambridge, USA., Root DE; Broad Institute of MIT and Harvard, Cambridge, USA., Stegmaier K; Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, USA.; Broad Institute of MIT and Harvard, Cambridge, USA.; Department of Pediatrics, Harvard Medical School, Boston, USA., Johannessen CM; Broad Institute of MIT and Harvard, Cambridge, USA. cory.johannessen@gmail.com., Beroukhim R; Broad Institute of MIT and Harvard, Cambridge, USA. Rameen_Beroukhim@dfci.harvard.edu.; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, USA. Rameen_Beroukhim@dfci.harvard.edu.; Division of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. Rameen_Beroukhim@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, USA. Rameen_Beroukhim@dfci.harvard.edu.
Publikováno v:
Nature communications [Nat Commun] 2019 Jun 03; Vol. 10 (1), pp. 2400. Date of Electronic Publication: 2019 Jun 03.
Autor:
Ghandi M; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Huang FW; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; University of California San Francisco, San Francisco, CA, USA., Jané-Valbuena J; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Kryukov GV; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Lo CC; Broad Institute of Harvard and MIT, Cambridge, MA, USA., McDonald ER 3rd; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Barretina J; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Gelfand ET; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Bielski CM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Li H; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hu K; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Andreev-Drakhlin AY; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Kim J; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Hess JM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Haas BJ; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Aguet F; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Weir BA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Rothberg MV; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Paolella BR; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Lawrence MS; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Akbani R; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lu Y; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tiv HL; Belfer Center for Applied Cancer Science, Boston, MA, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Boston, MA, USA., de Weck A; Novartis Institutes for Biomedical Research, Basel, Switzerland., Mansour AA; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Oh C; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Shih J; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Hadi K; New York Genome Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, Institute for Computational Biomedicine, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Rosen Y; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Bistline J; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Venkatesan K; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Reddy A; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Sonkin D; Novartis Institutes for Biomedical Research, Cambridge, MA, USA.; National Cancer Institute, Rockville, MD, USA., Liu M; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Lehar J; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Korn JM; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Porter DA; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Jones MD; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Golji J; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Caponigro G; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Taylor JE; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Dunning CM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Creech AL; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Warren AC; Broad Institute of Harvard and MIT, Cambridge, MA, USA., McFarland JM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Zamanighomi M; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Kauffmann A; Novartis Institutes for Biomedical Research, Basel, Switzerland., Stransky N; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Imielinski M; New York Genome Center, New York, NY, USA.; Department of Pathology and Laboratory Medicine, Englander Institute for Precision Medicine, Institute for Computational Biomedicine, and Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA., Maruvka YE; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Cherniack AD; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Tsherniak A; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vazquez F; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Jaffe JD; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Lane AA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Weinstock DM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Johannessen CM; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Morrissey MP; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Stegmeier F; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Schlegel R; Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Hahn WC; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Getz G; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Massachusetts General Hospital Cancer Center, Boston, MA, USA.; Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Mills GB; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Boehm JS; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Golub TR; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Howard Hughes Medical Institute, Chevy Chase, MD, USA., Garraway LA; Broad Institute of Harvard and MIT, Cambridge, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Sellers WR; Novartis Institutes for Biomedical Research, Cambridge, MA, USA. wsellers@broadinstitute.org.; Broad Institute of Harvard and MIT, Cambridge, MA, USA. wsellers@broadinstitute.org.
Publikováno v:
Nature [Nature] 2019 May; Vol. 569 (7757), pp. 503-508. Date of Electronic Publication: 2019 May 08.
Autor:
Howard TP; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Arnoff TE; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Song MR; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Giacomelli AO; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Wang X; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts., Hong AL; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Dharia NV; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Wang S; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts., Vazquez F; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Pham MT; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Morgan AM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wachter F; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Bird GH; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Kugener G; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Oberlick EM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Rees MG; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Tiv HL; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Hwang JH; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Walsh KH; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Cook A; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Krill-Burger JM; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Tsherniak A; Broad Institute of Harvard and MIT, Cambridge, Massachusetts., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Park PJ; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts., Stegmaier K; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Walensky LD; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Linde Program in Cancer Chemical Biology, Dana-Farber Cancer Institute, Boston, Massachusetts., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Charles.roberts@stjude.org william_hahn@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Roberts CWM; Department of Pediatric Oncology, Dana-Farber Cancer Institute and Division of Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts. Charles.roberts@stjude.org william_hahn@dfci.harvard.edu.; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Oncology, Comprehensive Cancer Center, St. Jude Children's Research Hospital, Memphis, Tennessee.
Publikováno v:
Cancer research [Cancer Res] 2019 May 01; Vol. 79 (9), pp. 2404-2414. Date of Electronic Publication: 2019 Feb 12.